01 Same-day alerts Critical changes hit your inbox the day they publish, not the next monthly digest.
02 Authority-source filter Pick your sources: DCC, CDTFA, state legislature, federal/DEA, your local jurisdiction.
03 License-type filtered Alerts scoped to your license types and SKUs — no noise from rules that do not touch you.
04 Operator-actionable Each alert names what to change, who owns it, and the citation behind it. Not just news.
Critical · Federal · April 22, 2026 · 21 USC §812 DOJ Schedule III rescheduling now in effect for state-licensed medicinal cannabis The DOJ’s administrative action under 21 USC §812 reschedules state-licensed medicinal cannabis to Schedule III. IRC §280E only applies to Schedule I/II controlled substances — medical operators no longer fall inside its scope. Adult-use remains Schedule I; the broader DEA rescheduling hearing is set for June 29, 2026. Affects Type 9, Type 10, Type 12 licensees with medical SKUs · Distribution Type 11 carrying medical product · Manufacturing Types 6, 7, N for medical formulations Operator actions, this week Open the conversation with your CPA on amended-return posture for medical-channel revenue. Segregate medical vs adult-use revenue lines for tax-year 2026 filing. Track the June 29, 2026 DEA hearing for broader rescheduling implications. Coordinate with retained tax counsel before acting on any §280E decision. Read the full operator briefing →